Arvinas Holding Company LLC (ARVN) stock plummeted 5.11% in the morning trading session on Tuesday, following the release of its fourth-quarter 2024 financial results. Despite beating earnings estimates, the biotech company missed revenue expectations, which likely contributed to the stock's decline.
For the quarter ended December 31, 2024, ARVN reported a net loss of $0.63 per share, narrower than the consensus estimate of a $0.96 loss per share. However, the company's revenue of $59.2 million fell short of analysts' expectations of $65.3 million.
On the positive side, ARVN provided an update on its cash runway, stating that its cash, cash equivalents, and marketable securities as of December 31, 2024, are sufficient to cover planned expenses and capital expenditures through 2027. This extended cash runway could provide the company with financial flexibility to advance its drug development programs and support operations.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。